4:43 PM ET
10-K
Financial Results
BriaCell Therapeutics FY 2026 Results: Net Loss of $34.9M, Loss Widens
BriaCell Therapeutics Corp. is a pre-revenue clinical-stage biotechnology company facing substantial competition and significant going concern risks. The company expects increased operating expenses as it advances its Phase 3 Bria-IMT™ and Phase 1/2 Bria-OTS™ clinical programs, while managing risks related to data security, key personnel retention, and its majority stake in BriaPro.
- Key figure
- Net loss $34.9M